세계 급성 골수성 백혈병 시장 : 질환별, 치료법별, 투여 경로별, 최종 사용자별 예측(2024-2032년)

Global Acute Myeloid Leukemia Market size will grow at 10.7% CAGR from 2024 to 2032, propelled by regulatory approvals for novel drugs and therapies for the disease treatment. Rapid advancements in treatment options and the ongoing R&D efforts are providing patients with access to more effective and targeted therapies for improving the overall outcomes. With strong focus on personalized medicine and innovative treatments, the acute myeloid leukemia (AML) industry will expand as new therapeutic options emerge while the existing treatments are optimized for enhanced efficacy. For instance, in December 2022, the FDA granted approval for OLU [89], an IDH1 inhibitor, for the treatment of relapsed or refractory (R/R) AML. This approval is based on a phase 1/2 trial involving patients with IDH1-mutant R/R AML who had not previously received IDH1 inhibitors

The acute myeloid leukemia market is segmented into disease type, treatment type, route of administration, end-user, and region.

Based on disease type, the industry size from the myelomonocytic leukemia segment will achieve 11.6% CAGR up to 2032, driven by its prevalence as it accounts for a significant portion of AML cases. Myelomonocytic leukemia is characterized by the presence of both myeloid and monocytic cells, requiring targeted treatment approaches. With advancements in understanding the molecular mechanisms of this subtype, tailored therapies are being developed, further contributing to the segment growth.

AML market size from the targeted therapy treatment type segment will foresee an 11.4% CAGR between 2024 and 2032. This is due to the efficacy and specificity of targeted therapies in treating AML, which often have fewer side effects compared to traditional chemotherapy. Drugs targeting specific mutations like FLT3, IDH1, and IDH2 are gaining prominence. The ongoing advancements in targeted therapy development and personalized medicine approaches for offering promising treatment options for patients will also drive the segment expansion.

Asia Pacific acute myeloid leukemia market will register a 12.3% CAGR from 2024 to 2032. The growth can be attributed to the increasing prevalence of AML, particularly in countries like China and Japan along with the rising aging population. Robust advancements in healthcare infrastructure are expanding the access to treatment options across the region. With the growing focus on personalized medicine and innovative therapies, Asia Pacific will further emerge as a key contributor in the acute myeloid leukemia industry.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of acute myeloid leukemia
    • 3.2.1.2 Advancement in research and technology
    • 3.2.1.3 Surging government initiative and policy
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of awareness and knowledge
    • 3.2.2.2 High cost associated with treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Myeloblastic leukemia
• 5.3 Myelomonocytic leukemia
• 5.4 Promyelocytic leukemia
• 5.5 Monocytic leukemia
• 5.6 Other leukemia types

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Chemotherapy
  • 6.2.1 Anti-metabolites
  • 6.2.2 Alkylating agents
  • 6.2.3 Anthracycline drugs
  • 6.2.4 Other chemotherapy types
• 6.3 Targeted therapy
• 6.4 Immunotherapy
• 6.5 Other treatment types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Parenteral
• 7.3 Oral

Chapter 8 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals & clinics
• 8.3 Specialty centers
• 8.4 Homecare settings
• 8.5 Ambulatory care centers

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Astellas Pharma Inc.
• 10.2 Bristol Myers Squibb Company
• 10.3 Celgene Corporation
• 10.4 Daiichi Sankyo Company, Limited
• 10.5 Jazz Pharmaceuticals plc
• 10.6 Novartis AG
• 10.7 Otsuka Pharmaceutical Co., Ltd.
• 10.8 Partner Therapeutics, Inc.
• 10.9 Pfizer Inc.
• 10.10 Rigel Pharmaceuticals, Inc.